crl4

Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.

Lenalidomide hemihydrate is a derivative of Thalidomide, an orally active immunomodulator that acts as a molecular gel. It is a ligand for the ubiquitin E3 ligase cereblon, which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase.

dCeMM3 (2-(1H-benzimidazol-2-ylsulfanyl)-N-(5-chloropyridin-2-yl)acetamide) is a glue degrader. dCeMM3 prompts an interaction of CDK12-cyclin K with a CRL4B ligase complex, result in inducing ubiquitination and degradation of cyclin K.

Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.

CRL-40940 is a selective dopaminergic reuptake inhibitor

Thalidomide-D4 is a deuterium labeled Thalidomide (T0213), has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.

Fladrafinil (CRL-40,941) is a nootropic.

CRL-42872 free base is a bioactive chemical.

CRL-42872 HCl is a bioactive chemical.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

DCAF1 Binder 1 selectively targets the CRL4 DCAF1 E3 ligase complex as a ligand, playing a role in targeted protein degradation (TPD) [1].

Lenalidomide (sodium), a Thalidomide derivative, serves as a molecular glue and an orally active immunomodulator. It acts as a cereblon (CRBN) ligand and triggers selective ubiquitination and subsequent degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 ubiquitin ligase. Echoing its specificity, Lenalidomide (sodium) inhibits the proliferation of mature B-cell lymphomas, notably multiple myeloma, and promotes IL-2 secretion from T cells [1] [2].

KH-4-43, an inhibitor of the E3 CRL4 ligase complex, demonstrates anticancer activity by targeting the core of the E3 CRL4. It exhibits a binding affinity (Kd) of 83 nM to the E3 ROC1-CUL4A CTD and 9.4 μM to the closely related ROC1-CUL1 CTD [1].

Lenalidomide-13C5,15N is a variant of Lenalidomide (T1642) labeled with 15N and 13C. Lenalidomide (T1642) (CC-5013), a derivative of Thalidomide, is an orally active immunomodulatory agent acting as a molecular glue. It serves as a ligand for the E3 ubiquitin ligase cereblon (CRBN), facilitating the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 ubiquitin ligase. Notably, Lenalidomide (T1642) (CC-5013) suppresses the growth of mature B cell lymphomas, including multiple myeloma, and stimulates T cells to release interleukin-2 (IL-2).

Lenalidomide-D5 is a deuterated form of Lenalidomide. Lenalidomide (T1642) (CC-5013) is a derivative of Thalidomide and acts as an orally active immunomodulator in a molecular glue manner. It serves as a ligand for the ubiquitin E3 ligase cereblon (CRBN). Through the CRBN-CRL4 ubiquitin ligase complex, Lenalidomide (T1642) selectively ubiquitinates and degrades the lymphocyte transcription factors IKZF1 and IKZF3. It effectively inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and induces T cells to release interleukin-2 (IL-2).